CClinicalTrials.gg
CompletedNCT05249257Updated Jan 19, 2023

Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity

An observational study in Cellulite, Laxity; Skin and Edematous Fibrosclerotic Panniculopathy, sponsored by Endo Pharmaceuticals. Completed at 3 sites in United States. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-01-19.

Sponsored by Endo Pharmaceuticals · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

All participants who completed the EN3835-224 study will be invited to participate in this observational study to evaluate long term durability of response and safety.

02

Conditions studied

  • Cellulite
  • Laxity; Skin
  • Edematous Fibrosclerotic Panniculopathy
03

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The Safety Population is defined as all participants who meet the inclusion/exclusion criteria at Day 360. All Safety analyses will be based on this population.

The Full Analysis Set (FAS) is defined as all participants in the Safety Population who have at least 1 I-GAIS assessment. All efficacy analyses will be based on this population.

Inclusion criteria

  1. Have participated in and completed study EN3835-224 (parent study).
  2. Be willing and able to cooperate with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Has received any collagenase treatments (eg, Santyl® Ointment) at any time since
  2. Has had any surgery, invasive procedure (eg, liposuction), injectable treatment (eg, KYBELLA®) or any similar treatment in the area treated during the EN3835-224 study since the completion of that study.
  3. Has any other conditions that, in the investigator's opinion, might indicate the participant to be unsuitable for the study
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • No Treatment - previously treated in parent study

    Participants who completed the parent study EN3835-224 (NCT04580303) will be eligible for this study.

05

What researchers measure

Primary outcomes

  1. Proportion of 1-level responders (+1 or better score) on the I-GAIS for either buttock or either thigh

    Investigator Global Aesthetic Improvement Scale (I-GAIS) is a 7-level scale ranging from "+3" (very much improved) to "-3" (very much worse) to determine the degree of improvement of the treated areas

    Time frame: Day 360

  2. Proportion of 1-level responders (+1 or better score) on the I-GAIS for either buttock or either thigh

    Investigator Global Aesthetic Improvement Scale (I-GAIS) is a 7-level scale ranging from "+3" (very much improved) to "-3" (very much worse) to determine the degree of improvement of the treated areas

    Time frame: Day 540

Secondary outcomes

  1. I-GAIS ratings

    Investigator Global Aesthetic Improvement Scale (I-GAIS) is a 7-level scale ranging from "+3" (very much improved) to a "-3" (very much worse) to determine the degree of improvement of the treated areas.

    Time frame: Day 360 and Day 540

  2. Proportion of 1-level responders (+1 or better score) on the S-GAIS for either buttock or either thigh

    Subject Global Aesthetic Improvement Scale (S-GAIS) is a 7-level scale ranging from "+3" (very much improved) to a "-3" (very much worse).

    Time frame: Day 360 and Day 540

  3. Change from Day 1 (pre-treatment) of the parent study and each study visit in Subsection D of the Hexsel CSS

    Hexsel CSS is a photonumeric scale that looks at 5 key morphologic features of cellulite using a 4-point scale ranging from "0" (low) to "3" (high).

    Time frame: Day 360 and Day 540

06

Study locations

3 sites
  • Endo Clinical Trial Site #2
    Coral Gables, Florida 33146, United States
  • Endo Clinical Trial Site #3
    Metairie, Louisiana 70006, United States
  • Endo Clinical Trial Site #1
    New York, New York 10021, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05249257
Lead sponsor
Endo Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 21, 2022
Start date
Jan 25, 2022
Primary completion
Sep 12, 2022
Completion
Sep 12, 2022
Last update
Jan 19, 2023

Study contacts

Karen Chajko
study director · Endo Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion